CareDx Inc (CDNA) reported quarterly earnings results on Friday, May-6-2016. The company reported $-0.37 earnings per share for the quarter, missing the analyst consensus estimate by $-0.06. Analysts had a consensus of $-0.31. The company posted revenue of $6.60 million in the period, compared to analysts expectations of $6.97 million. The company’s revenue was down -8.3% compared to the same quarter last year. During the same quarter in the previous year, the company posted $-0.19 EPS.
CareDx Inc closed down -0.06 points or -1.39% at $4.27 with 554 shares getting traded on Wednesday. Post opening the session at $4.31, the shares hit an intraday low of $4.27 and an intraday high of $4.32 and the price fluctuated in this range throughout the day.Shares ended Wednesday session in Red.
In a different news, on Jun 3, 2015, Peter Maag (CEO) purchased 2,000 shares at $4.84 per share price.
CareDx Inc. formerly XDx Inc. is a commercial-stage company which develops markets and delivers a diagnostic surveillance solution for heart transplant recipients. The Company’s commercialized testing solution the AlloMap heart transplant molecular test or AlloMap is a non-invasive blood-based test used to monitor heart transplant recipients for acute cellular rejection. AlloMap uses gene expression technology for the identification of heart transplant recipients. AlloMap provides a single integer score ranging from 0 to 40 and determines the probability of moderate to severe acute cellular rejection. As of December 31 2014 the Company performed more than 66000 commercial AlloMap tests in total. The Company is also engaged in the new product development in other areas of transplant surveillance such as the use of cell-free donor de-oxy ribonucleic acid (cfDNA) technology as a biomarker for rejection.